Targeted therapy reduces risk of lung cancer recurrence by 83% in rare genetic subtype
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare ...
Jun 1, 2026
0
4









